An independent panel’s interim analysis of Eli Lilly and Co’s breast cancer drug abemaciclib showed the treatment did not meet the effectiveness criteria in a late-stage trial.
The panel recommended the trial continue through the first half of 2017, the company said on Wednesday.
Read more.
Filed Under: Drug Discovery
